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Abstract
 .The cardioprotective effects of EGb 761 on the release of nitric oxide NO , the concentration of serum thiobarbituric
 .  .acid reaction substance TBARS , the activity of creatine kinase CK and the incidence of ventricular arrhythmias were
 .investigated in myocardial ischemia-reperfusion injury in vivo. Using sodium nitrite NaNO as standard source of nitric2
 .oxide NO , we compared the correlation coefficients of the three measuring methods used currently in the determination of
2q .NOFe DETC complex with that of the measuring method suggested in this study. The result showed that measuring the2
whole height of three splitting signals is the best linear correlation to the concentration of NO comparing with other
2q .methods in this system. Using this method, we observed the effects of EGb 761 on NOFe DETC complex in2
myocardial ischemia-reperfusion injury in vivo. The hearts of the Wistar rats were subjected to 30 min of ischemia and 10
 .  4min of reperfusion in vivo. Different doses of EGb 761 25, 50, 100, 200 mgrkg i.p. , superoxide dismutase SOD, 10
.  .  . G  .Urkg , L-arginine 50 mgrkg i.p. and nitric oxide synthase NOS inhibitor N -nitro-L-arginine NNA, 50 mgrkg i.p.
were administered to the ischemia-reperfusion rats. EGb 761 under the dose of 100 mgrkg increased the signal intensity of
2q .NOFe DETC complex, while EGb 761 at 200 mgrkg showed an effect of decreasing the signal intensity of2
2q .NOFe DETC complex. EGb 761 inhibited the formation of TBARS, the release of CK, and mitigated the incidence of2
2q .ventricular arrhythmias in a dose dependent way. Both L-arginine and SOD increased the signal intensity of NOFe DETC 2
complex and inhibited the formation of TBARS, the leakage of CK and the incidence of ventricular arrythmia. NNA not
only had no protective effects on myocardial injury, but also increased the incidence of reperfusion-induced arrhythima. In
conclusion, EGb 761 has cardiovascular protective effects by means of adjusting the level of NO and inhibiting oxygen free
radicals induced lipid peroxidation in myocardial ischemia-reperfusion injury in vivo. q 1998 Elsevier Science B.V. All
rights reserved.
 . 2q .Keywords: Ginkgo biloba extract EGb 761 ; NOFe DETC ; L-Arginine; Lipid peroxidation; Creatine kinase; Arrhythmia; Myocar-2
dial ischemia-reperfusion injury
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leukocytes; ECG, electrocardiogram; HR, heart rate; AR, arrhythmias rate; SR, sinus rhythm; VT, ventricular tachycardia; VF, ventricular
fibrillation
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1. Introduction
EGb 761 is a specific and complex product pre-
pared from Ginkgo leaves that has been used in
traditional Chinese medicine for thousands years.
Currently, Ginkgo biloba extract is widely used in
treating cardiovascular diseases and cerebral vascular
w xdiseases in many countries 1 . Its main ingredients
are ginkgo-flavone glycosides and terpenoids. Be-
cause the chemical ingredients of Ginkgo biloba ex-
tract are complex and the extract method is different
with different investigators, the biological effects of
Ginkgo biloba extract are hard to be evaluated. EGb
761 is a standardized products on the amount of 24%
ginkgo-flavone glycosides and 6% terpenoid. It is
known that EGb 761 has protective effects against
cardiac reperfusion-induced arrhythmias and func-
tional damages in the ischemic-reperfused rat hearts,
whose cardiovascular effects rely on its properties of
w xscavenging free radicals 2–9 . As it has properties of
scavenging superoxide anions, the cardiovascular
molecular mechanisms of EGb 761 have also been
hypothesized to include prolongation of the half-life
 .of endothelium-derived relaxing factor EDRF and
w xenhancement of the cellular action of EDRF 10 .
However, EGb 761 is a scavenger of NO in vitro
w xacellular systems under physiological condition 11 .
Our previous study showed also that EGb 761 could
scavenge NO and oxygen free radicals in isolated
hearts subjected to ischemia and reperfusion in vitro
w x12 . The effect of EGb 761 on the generation of NO
in ischemia-reperfusion myocardial in vivo has not
been reported, which is a limitation with regard to the
full understanding of the effects of EGb 761.
It is believed that NO has a ‘double edged’ action
in biological systems. It has potentially useful effects
such as inhibition of platelet aggregation and poly-
 . wmorphonuclear leukocytes PMN adhesion etc. 13–
x17 , and also cytotoxic effects by means of reaction
with superoxide anions and consequent formation of
 y. w xperoxynitrite ONOO 18,19 . Peroxynitrite dam-
ages the components of cells directly and decom-
poses into low molecular toxic products, such as
nitrogen dioxide radicals, hydroxyl radical and nitron-
w xium, etc. 20,21 . NO combines with iron-containing
proteins, such as aconitase and ribonuclecotide reduc-
tase, resulting in the formation of iron-nitrosyl com-
wplexes and the impairment of cellular functions 22–
x24 . Overstatement using different protocol and mod-
els it is possible to reveal benefit, no effect and
detriment by modulation of NO homeostasis
w x16,17,25–28 . In addition, many studies used L-
 .arginine or inhibitor of inducible NO synthase iNOS
to observe the effect of NO in myocardial ischemia-
w xreperfusion injury without determination of NO 27 .
According to our pervious observation, the generation
of NO did not parallely increase with the concentra-
tion of L-arginine in myocardial ischemia and reper-
w xfusion injury in vitro 29 . The benefit and detrimen-
tal effects of NO depend on the concentration of NO
in the biological system. Low level of NO produced
constitutively by endothelial constitutive NO syn-
 .thase ecNOS plays a physiological role in blood
w xpressure regulation 30 , whereas high level of NO
produced by iNOS has cytotoxic effect during in-
flammation after lipopolysaccharide and cytokine
w xchallenge 31 . Therefore, it is necessary to develop a
method to detect NO directly and accurately to evalu-
ate the cardiovascular effects of L-arginine-NO path-
way and the action of EGb 761 on NO in myocardial
ischemia-reperfusion injury in vivo.
NO has high affinity to ferrous-containing protein
and formation of iron-nitrosyl complexes. Recently,
2q .iron diethyldithiocarbamate Fe DETC has been2
used to trap specifically and detect directly NO
formed in animal tissues in vivo from exogenous and
w xendogenous sources 32–36 . The resultant formation
of a stable paramagnetic mononitrosyl iron complex
2q  .NOFe DETC can be characterized by an ESR2
signal at g s2.035 and g s2.020 with tripletH 5
 .hyperfine structure HFS at g . The relatively sta-H
2q .ble radical NOFe DETC can be detected by2
w xcryogenic ESR spectroscopy 32 . However, there are
three methods to measure the signal intensity of NO
without an unified standard in current reports, such as
determination by the first low-field derivative ESR
w xsignal height 32,33 , or by the third high-field
w xderivative ESR signal height 34 , or by the height
between the top of the first ESR low-field signal and
w xthe valley of the third-high-field signal 35 . None of
these ESR methods has considered the relationship
between the splitting degree of triplet characteristic
signal and the content of NO. Therefore, the method
that measures the whole height of three splitting
signals in ESR spectra to represent the signal inten-
sity of NO was suggested in this study. Sodium
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nitrite, a standard source of NO, was used to evaluate
which method is most related to NO in solution
w xsystem 37 . The effects of EGb 761 on the ESR
2q .signal intensity of NOFe DETC complex, the2
incidence of ventricular arrhythmias, the release of
CK and the generation of TBARS were investigated
in the ischemia-reperfused myocardia in vivo.
2. Material and methods
2.1. Reagents
EGb 761 was obtained from IPSEN institute,
France. Sodium N, N-diethyldithiocarbamate trihy-
 .drate DETC was purchased from Aldrich
 .  .Milwaukee, WI . Superoxide dismutase SOD , L-
G  .arginine, N -nitro-L-arginine NNA , sodium nitrite,
 .bovine serum albumin BSA , thiobarbituric acid
 .TBA , 1,1,3,3-tetramethoxypropane were purchased
 .from Sigma St. Louis, MO . Kit for measuring CK
activity was purchased from Zhong Sheng Bio Tech
 .Beijing, China . Other compounds purchased from
China were analytical grade.
2q( )2.2. Measurement of NOFe DETC in solution by2
ESR
DETC was dissolved in 10% BSA. NaNO were2
dissolved in distilled water at 1.0 mM before use.
FeSO P7H O was dissolved in dilute HCl solution.4 2
After being mixed with DETC final concentration 33
.  .mgrml and FeSO P7H O 3.3 mM , different con-4 2
centrations of NaNO final concentration 10, 20, 30,2
.40, 60 100 mM were added into the system respec-
 .tively, and then excess Na S O 2 M was added,2 2 3
and the mixture solution was introduced into a 3
diameter quartz tube and put into liquid nitrogen
immediately. ESR spectra were measured in a Varian
109-E spectrometer at 100 K. The ESR condition is
as follows: 9.13 GHz microwave frequency, 10 mW
microwave power, 100 kHz modulation frequency,
0.32 mT modulation amplitude, and 0.128 s time
constant.
2.3. Ischemia-reperfusion hearts in ˝i˝o
 .Male Wistar rats 250–300 g were obtained from
Institute of Genetics, Academia Sinica. The rats were
anaesthetized with 1.5% pentobarbital 50 mgrkg
.wt. intraperitoneally. All reagents in physiological
salt solution were injected into rats intrapertioneally
 .  2qi.p. except Fe -citrate complex, which was ad-
.ministered subcutaneously in the thigh at 30 min
prior to the onset of ischemia at the following doses:
DETC 500 mgrkg wt., Fe-citrate 50 mg FeSO P4
.7H O-250 mg sodium citraterkg wt. , EGb 761 25,2
50, 100, 200 mgrkg wt., SOD 104 Urkg wt., L-
arginine 50 mgrkg wt., and NNA 50 mgrkg wt.,
respectively. The rats were divided randomly into
2q .groups as follows: controlqDETCrFe N ; is-
2q .chemia q DETCrFe I ; ischemiarreperfusion q
2q  .D ETCrFe IR ; ischem iar reperfusion q
2q DETCrFe qEGb 761 25,50,100,200 mgrkg wt.
.  .each IR q EGb 761 ; ischemiarreperfusion q
2q  .  .DETCrFe qL-arginine 50 mgrkg wt. IRqLA ;
2q ischemiarreperfusion q DETCrFe q L-NNA 50
.  .mgrkg wt. IRqNNA ; and ischemiarreperfusion
2q  4 .  .qDETCrFe qSOD 10 Urkg wt. IRqSOD .
The rats were subjected to tracheotomy and supplied
with artificial respiration. After being operated
through left thoracotomy, the hearts were subjected to
30 min of ischemia by ligating the main branch of the
 .left coronary artery LCA with a plastic pipe. At the
onset of 30 min of ischemia, the plastic pipe was
removed to produce reperfusion. After 10 min of
reperfusion, the heart was rapidly excised and cut
into small cylinders of 2.5 mm diameter with cold
scissors which were previously in liquid nitrogen, and
put immediately into a quartz tube of 3 mm diameter
packed 3 cm in height, and then placed in liquid
nitrogen for ESR measurement. The ESR spectrome-
ter condition is the same as the solution system. The
blood sample was collected by cardiac puncture at
the end of reperfusion. Serum was separated immedi-
ately by centrifugation at 48C for the analysis of CK
and TBARS.
2.4. CK acti˝ity measurement
Serum CK activity were measured by means of the
enzyme dynamic method using Beckman DU-640
spectrophotometer with Zhong Sheng Biological
standard reagents.
2.5. TBARS measurement
Serum TBARS content was measured by means of
the Ohkawa’s method at 532 nm using Beckman
w xDU-640 spectrophotometer 38 .
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2.6. Arrhythmia diagnosis and ECG analysis
 .All electrocardiograms ECG were monitored at
standard I by a polygraph throughout the experimen-
 .tal period. Heart rate HR was derived from these
recordings and counted during ischemia-reperfusion
progress. Arrhythmias were defined according to the
w xLambeth conventions 8,38 . If normal sinus com-
plexes occurring in a regular rhythm were present on
 .the ECG, it was considered as sinus rhythm SR . A
discrete and identifiable premature QRS complex was
diagnosed as ventricular premature; a ventricular pre-
mature beats occurring regularly with one or two
normal sinus complexes were identified as bigeminy
and trigeminy respectively; a run of four or more
ventricular premature beats was identified as ventric-
 .  .ular tachycardia VT . Ventricular fibrillation VF
was defined as a signal from which individual QRS
deflections vary in amplitude and coupling interval
on a cycle-to-cycle basis. The incidence of ventricu-
lar arrhythmias was obtained from the ECG.
2.7. Statistics
The Data were expressed as Mean"S.E.M. and
analysed by ANOVA. Comparison between the treat-
ment groups was made by analysis of Newman–Ke-
uls test. When p-0.05 statistical significance was
accepted.
3. Results
2q ( )3.1. ESR measurement of NOFe DETC complex2
in solution system
2q  .The ESR spectrum of NOFe DETC complex2
 . 2qwas obtained from NaNO 0.1 mM , Fe and2
DETC. As shown in Fig. 1, the height of three
hyperfine splitting was defined as h , h , and h1 2 3
respectively. The first low field signal was defined as
H , the height of the third high field signal was0
defined as H and the perpendicular height between3
the top of the first lower field signal and the valley of
the third high field signal was defined as H . Thew
whole height of three splitting signals was defined as
Fig. 1. The measuring methods of ESR spectra of
2q  .N O Fe D ETC com plexes in solution system .2
2q  .  .NOFe DETC complex was obtained with NaNO 30 mM2 2
as a NO source. The reaction mixture containing 33 mgrml PSA,
2q  .3.3 mM Fe , 3.3 mM DETC, and excess Na S O 2 M . H :2 2 4 I
h q h q h . The linear regression equation and the correlation1 2 3
coefficient rates were as follows: H : Y s7.5232q0.8446 X,0
r s0.9849, H : Y s4.3355q0.6569X, r s0.9766, H : Y s3 w
14.2480q1.5056 X, r s0.9801 and H : Y s12.460q2.1965X,1
r s0.9931. The details of ESR conditions were described in
Section 2.
 .H h qh qh . All the intensity of the ESR sig-1 1 2 3
nals based on the measuring methods increased lin-
early with the NO concentrations. After linear regres-
sion analysis, the correlation coefficient rates were as
follows: H : Ys7.5232q0.8446 X, rs0.9849, H :0 3
Y s 4.3355 q 0.6569 X , r s 0.9766, H : Y sw
14.2480q1.5056 X, rs0.9801 and H : Ys12.460I
q2.1965X, rs0.9931. H was the best correlationI
with the concentration of NO. Therefore, measuring
the whole height of three splitting signals is the best
way to represent the concentration of NO comparing
with other methods in this system.
3.2. Effects of EGb 761 on the signal intensity of
2q ( )NOFe DETC complexes in ischemia-reperfusion2
injury in ˝i˝o
2q  .Fig. 2 shows the ESR spectra of NOFe DETC 2
complexes in myocardia of ischemia-reperfusion. Ad-
ministration of DETCrFe2q to normal rat showed a
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2q  .small characteristic ESR signal of NOFe DETC 2
complex which is characterized by g s2.035 asH
. w x1.3 mT , g s2.020 23–26 . A peak at gs2.0475
and a shallow trough at gs2.02 were observed from
the spectrum. The height of H could be consideredI
as a normal physiological level of NO. After 30 min
of ischemia, the ESR signal intensity of
2q .NOFe DETC complex in myocardium was in-2
creased remarkably. When rat heart was subjected to
30 min of ischemia following 10 min of reperfusion,
2q .the signal intensity of NOFe DETC of the is-2
chemia-reperfused myocardium was significantly
lower than that of only ischemia myocardium. It
2q .suggests that the signal intensity of NOFe DETC 2
2q  .Fig. 2. ESR Spectra of NOFe DETC complexes in myocar-2
 .  . 2q  .dia of ischemia-reperfusion. a Normal N qDETCrFE ; b
 . 2q  .  .Ischemia I qDETCrFe ; c Ischemiarreperfusion IR q
2q  . 2q DETCrFe ; d IRqDETCrFe qL-arginine 50 mgrkg wt,
.  . 2q  4 .  .i.p. ; e IRqDETCrFe qSOD 10 Urkg wt., i.p. . f
2q  .IRqDETCrFe qNNA 50 mgrkg wt., i.p. ; The details of
ESR conditions were described in Section 2.
Table 1
2q  .Effects of EGb 761 on myocardial NOFe DETC complex2
  .arbitrary units, serum TBARS concentration nmolrml and CK
 .activities UrL in myocardial ischemia-reperfusion injury in
 .vivo. Mean"S.E.
2qGroup n NOFe TBARS CK
 .DETC 2
N 9 28.50"1.25 7.38"0.38 423"33
a aI 10 62.75"5.65 7.92"0.24 2307"122
a aIR 16 29.31"1.74 10.23"0.62 3524"254
IRq
EGb 761
25 6 40.33"3.46)) 9.95"0.31 3227"195
50 6 62.17"3.36)) 8.82"0.68) 2342"164))
100 6 85.17"5.96)) 8.46"0.33) 1691"173))
200 6 39.50"4.01) 7.50"0.17)) 1720"245))
IRq
SOD 9 50.11"3.69)) 7.84"0.31)) 2120"242)
IRq
LA50 8 61.67"6.44)) 8.32"0.42) 2367"200))
IRq
NNA50 10 20.10"2.47)) 9.63"1.07) 3142"440))
N: normal control heart, I: ischemia heart, IR: ischemia-reperfu-
 .sion heart, EGb 761 25, 50, 100, 200) mgrkg, i.p. . SOD:
 4 . superoxide dismutase 10 Urkg wt., i.p. . LA50: L-arginine 50
. G  . amgrkg, i.p. . NNA50: N -nitro-L-arginine 50 mgrkg, i.p. :
Vs N, p-0.01; ), Vs IR, p-0.05; )), Vs IR, p-0.01.
increased during ischemia stage and decreased during
reperfusion stage. The signal intensity was increased
 .by administration of L-arginine 50 mgrkg wt. and
 .decreased by administration of NNA 50 mgrkg wt. ,
2q .indicating that the signal of NOFe DETC com-2
plex originates from NO. The signal intensity of
2q .NOFe DETC complex also increased signifi-2
 4 .cantly by administration of SOD 10 Urkg wt. ,
indicating that superoxide anions contribute to the
decrease of NO level in the ischemia-reperfusion
myocardium. The data measured from the whole
height of three splitting signals were shown in Table
1.
As shown in Table 1, the signal intensity of
2q .NOFe DETC complexes increased with the doses2
of EGb 761 under 100 mgrkg wt. It is interesting
that the signal intensity in the 200 mgrkg EGb 761
group was significantly lower than that of 100 mgrkg
EGb 761 group. It suggests that low dose of EGb 761
increases the level of NO, while high dose of EGb
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Table 2
Influence of EGb761 on heart rates in myocardial ischemia-reper-
 .fusion injury in vivo. Mean"S.E.
Group n Normal stage Ischemia stage Reperfusion stage
N 9 330"14 y y
I 10 334"8 346"14 y
IR 16 325"13 373"18 392"31
IRq
EGb761
25 6 343"17 320"27) 343"15
50 6 350"11 373"18 363"14
100 6 337"14 333"14 310"10)
200 6 323"13 310"20) 327"15)
IRq
SOD 9 351"13 325"23) 348"16
IRq
LA 8 320"18 295"11) 303"23)
IRq
NNA 10 338"8 310"15) 273"19))
N: normal control heart, I: ischemia heart, IR: ischemia-reperfu-
 .sion heart, EGb 761 25, 50, 100, 200) mgrkg, i.p. . LA:
 . G L-arginine 50 mgrkg, i.p. , NNA: N -nitro-L-arginine 50
.mgrkg, i.p. . Vs IR, p-0.05; )), Vs IR, p-0.01.
761 has scavenging effect on NO in ischemia-reper-
fusion myocardium in vivo.
3.3. Effects of EGb 761 on serum TBARS concentra-
tion and CK acti˝ity in ischemia-reperfusion injury in
˝i˝o
In order to understand the relationship between the
different effects of EGb 761 on NO and its cardio-
vascular effects in myocardial ischemia-reperfusion
injury in vivo, we investigated lipid peroxidation and
enzyme leakage from the ischemia-reperfusion my-
ocardium. TBARS is widely used as a method for
lipid peroxidation induced by oxygen free radicals in
myocardial ischemia-reperfusion process. CK is a
classical method to evaluate the degree of myocardial
damage. Serum TBARS concentrations and CK activ-
ities in different experimental conditions were shown
in Table 1. Serum TBARS concentration and CK
activity were at low level in control heart. After 30
min of ischemia, serum TBARS concentration and
CK activity increased significantly. When the rat
heart was subjected to 30 min of ischemia following
10 min of reperfusion, serum TBARS concentration
and CK activity further increased significantly. It is
interesting that administration of L-arginine 50
.mgrkg wt. to the ischemia-reperfusion heart de-
creased significantly serum TBARS concentration and
CK activity. However, there was no significant dif-
ference with or without administration of NNA 50
.mgrkg wt. in ischemia-reperfusion rats. Administra-
 4 .tion of SOD 10 Urkg wt. to the ischemia-reperfu-
sion heart also inhibited significantly the serum
TBARS concentration and the CK activity. It sug-
gests that L-arginine at this concentration has in-
hibitory effects on lipid peroxidation and cardiac
injury. The scavenger of superoxide anions could
inhibit lipid peroxidation and prevent cardiac damage
in ischemia-reperfusion injury in vivo. It was also
Table 3
Influence of EGb761 on ventricular arrhythmias in myocardial ischemia-reperfusion injury in vivo
 .Group n BG TG VP VF VT TAR %
 .  .  .  .  .N 9 0r9 0 0r9 0 0r9 0 0r9 0 0r9 0 0
 .  .  .  .  .I 10 0r10 0 0r10 0 0r10 0 1r10 10 0r10 0 10
 .  .  .  .  .IR 16 0r16 0 0r16 0 3r16 18.75 3r16 18.75 1r16 6.25 43.75
IRqEGb761
 .  .  .  .  .25 6 0r6 0 0r6 0 0r6 0 1r6 16.67 0r6 0 16.67
 .  .  .  .  .50 6 0r6 0 0r6 0 0r6 0 1r6 16.67 0r6 0 16.67
 .  .  .  .  .100 6 0r6 0 0r6 0 0r6 0 0r6 0 0r6 0 0
 .  .  .  .  .200 6 0r6 0 0r6 0 0r6 0 0r6 0 0r6 0 0
 .  .  .  .  .IRqSOD 9 1r9 11.11 0r9 0 1r9 11.11 0r9 0 0r9 0 22.22
 .  .  .  .  .IRqLA 8 0r8 0 0r8 0 1r8 12.5 1r8 12.5 0r8 0 25.00
 .  .  .  .  .IRqNNA 10 1r10 10 1r10 10 2r10 20 1r10 10 0r10 0 50.00
 .Results is showed as ‘arrhythmias casertotal case % ’. BG: bigeminy, TG: trigeminy, VP: ventricular premature beat, VF: ventricular
fibrillation, VT: ventricular tachycardia, TAR: total arrhythmias rate, N: normal control heart, I: ischemia heart, IR: ischemia-reperfusion
 .  . G  .heart, EGb 761 25, 50, 100, 200) mgrkg, i.p. . LA:L-arginine 50 mgrkg, i.p. , NNA: N -nitro-L-arginine 50 mgrkg, i.p. . Vs IR,
p-0.05; )), Vs IR, p-0.01.
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 .shown that EGb 761 50–200 mgrkg inhibited sig-
nificantly serum TBARS concentrations and CK ac-
tivities in myocardial ischemia-reperfusion injury in
vivo in a dose-dependent way. It suggests that EGb
761 has cardioprotective effects by means of scav-
enging oxygen free radicals in myocardial ischemia-
reperfusion injury in vivo.
3.4. Effects of EGb 761 on the incidence of
ischemia-reperfusion induced arrhythmias and heart
rates in myocardial ischemia-reperfusion injury in
˝i˝o
Tables 2 and 3 shows the changes of heart rates
and the incidence of ischemia-reperfusion induced
ventricular arrhythmias respectively at different ex-
perimental conditions. After 30 min of ischemia fol-
lowing 10 min of reperfusion, the heart rates and the
incidence of ventricular arrhythmias were signifi-
cantly increased, which included ventricular prema-
ture beats, bigeminy, trigeminy, ventricular tachycar-
dia and ventricular fibrillation. Administration of
 .NNA 50 mgrkg wt. to the ischemia-reperfusion
heart decreased heart rates and increased the inci-
dence of ventricular arrhythmias significantly. Ad-
 .ministration of L-arginine 50 mgrkg wt. to the
ischemia-reperfusion hearts inhibited significantly the
heart rates and the incidence of ventricular arrhyth-
 4 .mias. Administration of SOD 10 Urkg wt. also
inhibited significantly the incidence of reperfusion-
induced ventricular arrhythmia. It suggests that L-
arginine and SOD in this concentration could miti-
gate the incidence of ventricular arrhythmias and
inhibit the heart rates in myocardial ischemia and
reperfusion injury in vivo. It was also shown that
EGb 761 had a dose-dependent inhibitory effects on
the incidence of ventricular arrhythmias and heart
rates.
4. Discussion
It is reported that EGb 761 has cardioprotective
effects in myocardial ischemia-reperfusion injury,
such as preventing reperfusion-induced arrhythmias,
improving postischemic myocardial function, and
w xmodulating microcirculation, etc. 3–6 , The cardio-
protective mechanisms of EGb 761 were attributed to
its properties of scavenging superoxide anions, hy-
w xdroxyl radicals and oxyferryl radicals 1,7 . The vas-
cular effects of EGb 761 were hypothesized to pro-
long the half-life of EDRF and enhance the cellular
w xaction EDRF 10 . However, it was reported that EGb
761 has NO-scavenging properties in acellular system
w x11 . Our recent study has further demonstrated that
EGb 761 has scavenging effects on NO in isolated
w xischemia-reperfusion heart 12 . It is indispensable to
observe the effects of EGb 761 on NO and evaluate
its consequent cardiovascular action in myocardial
ischemia-reperfusion injury in vivo. Therefore, we
investigated the effects of EGb 761 on the signal
2q .intensity of NOFe DETC complexes in vivo2
model of the ischemia-reperfusion hearts. The con-
centration of TBARS, the activity of CK and the
incidence of ischemia or reperfusion-induced arrhyth-
mias were also examined.
DETC and iron is a kind of NO trapping reagents,
which form a stable paramagnetic mononitrosyl iron
2q .complex-NOFe DETC . The complex has a char-2
acteristic triplet splitting signal in ESR spectrum.
Currently, there are three different ways to measure
2q .the signal intensity of NOFe DETC complex,2
which have relative linear correlation to the concen-
tration of NO. However, those methods have not
considered the signal splitting degree that should be
contributed by NO theoretically. Therefore, a new
method that measures the whole height of three split-
ting peaks was introduced in the study. Linear regres-
sion analysis showed that it had higher correlation to
the concentration of NO than the current three meth-
ods. Using this method, the signal intensity of
2q .NOFe DETC complex were measured in the my-2
ocardia of ischemia-reperfusion in vivo. It increased
at the ischemia period but decreased at reperfusion
period in ischemia and reperfusion myocardium. The
signal intensity was enhanced by L-arginine and in-
hibited by NNA. The results demonstrated directly
that the production of NO was increased in ischemia
period and decreased in the reperfusion period.
Meanwhile, different doses of EGb 761 showed dif-
ferent effects on the signal intensity of
2q .NOFe DETC complex in ischemia-reperfusion2
hearts in vivo. EGb 761 increased the signal intensity
2q .of NOFe DETC complex under the dose of 1002
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mgrkg. By virtue of the scavenging properties of
EGb 761 on superoxide anions, the augmentation of
2q .NOFe DETC complex may be attributed to pro-2
longing the half life of NO by means of scavenging
OPy and preventing the generation of ONOOy. It is2
2q .interesting that the NOFe DETC complex signal2
intensity was significantly decreased after administra-
tion of EGb 761 at 200 mgrkg wt., indicating strongly
that EGb 761 at high dose has NO-scavenging prop-
erties in myocardial ischemia-reperfusion injury in
vivo. Why different doses of EGb 761 showed differ-
ent effects on NO in the myocardial ischemia-reper-
fusion injury? The possible explanation may be that
EGb 761 has different reactive rates in the reaction
with OPy and NO. During ischemia-reperfusion2
progress, oxygen burst causes remarkable increase in
the generation of OPy. EGb761 at low dose may2
mainly scavenges OPy and in consequence increase2
the level of NO by preventing the reaction with OPy2
in such case. When high dose of EGb 761 is adminis-
tered to the ischemia-reperfusion myocardium, it
shows the antioxidant properties of scavenging both
NO and OPy simultaneously. Therefore, the signal2
2q .intensity of NOFe DETC complex is decreased2
significantly in such case. Although it had scavenging
2q .effect on NO, the signal intensity of NOFe DETC 2
complex in the ischemia-reperfusion group with 200
mgrkg EGb 761 was still higher than that in the
ischemia-reperfusion group without EGb 761.
In order to clarify the relationship between the
different effects of EGb 761 and its cardiovascular
effects, the concentration of TBARS, the leakage of
CK and the incidence of reperfusion-induced ventric-
ular arrhythmias were investigated. EGb 761 inhib-
ited significantly lipid peroxidation, myocardial dam-
age and the incidence of ventricular arrhythmias in a
dose dependent way. Although the level of NO in the
rat heart administered with 200 mgrkg of EGb 761 is
lower than that in the rat heart administered with 100
mgrkg of EGb 761, it still showed better cardiopro-
tective effects in myocardial ischemia-reperfusion in-
jury in vivo. It suggests that other protective mecha-
nisms could be involved in the cardiovascular effects
of EGb 761 in the process. For observing the effects
of NO in ischemia-reperfusion injury, L-arginine 50
.  .mgrkg and NNA 50 mgrkg were administered to
the ischemia-reperfusion hearts respectively. L-
 .arginine 50 mgrkg decreased serum TBARS con-
centration and CK activity and inhibited the inci-
dence of ventricular arrhythmias, while NNA 50
.mgrkg aggravated the cardiac damage and increased
incidence of ventricular arrhythmias in the ischemia-
reperfusion hearts. In addition, SOD has similar pro-
tective effects on ischemia-reperfusion myocardium
to L-arginine. The results suggest that both L-
arginine-NO pathway and antioxidants could inhibit
lipid peroxidation and protect the ischemia-reperfu-
sion heart in the system. EGb 761 has different
effects on NO in vivo and in vitro systems. The
different regulative properties on NO rely on the
concentration of EGb 761 in myocardial ischemia-re-
perfusion injury in vivo. It is an important cardiopro-
tective mechanism of EGb 761.
EGb 761 is a standard mixture of different con-
stituents which contains 24% flavonoids and 6%
terpenoids. It was reported that the flavonoid con-
stituents of EGb 761 lowered the concentration of
detectable superoxide anions in both enzymatic and
non-enzymatic systems. The most effective inhibitors
of Oy generation by phenazine methosulfate and2
w xNADH were quercetin, myricetin and rutin 9 . The
antioxidant properties of flavonoids are common to
aglycons and glycosides of flavonols and flavans, and
they are involved in breaking the chain reaction of
free radicals. The flavonol glycosides of EGb 761
may directly prolong the half-life of EDRF by scav-
enging Oy in the areas of thrombin adhering to2
w xvascular walls 10 . It might explain partly the cardio-
vascular protective mechanisms of EGb 761. In addi-
tion, terpenoids such as ginkgolide B revealed the
 .properties of platelet activating factors PAF -
antagonists, which could inhibit PAF-primed PMN
adhesion, Oy generation and elastase release, as well2
as PMN-mediated endothelial lysis and detachment
w x39,40 . PMN adhesion brings into a series of events
involving activation, disapedesis and extravascular
migration into neighbouring cardiac myocytes. It in-
duces the releases of proteolytic enzymes and oxygen
free radicals which contribute to enhancing microvas-
w xcular permeability and enlarging infract size 16,17 .
Terpenoids, by inhibiting PMN adhesion, should also
contribute to the cardiovascular protective mecha-
nisms of EGb 761 in the myocardial ischemia reper-
fusion injury in vivo. Therefore, the cardioprotective
mechanism of EGb 761 could be due to the interac-
tion of different antioxidant ingredients.
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